Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19957396 | 0.93 | TLR8 (0.53) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL21795382 | 0.85 | TLR8 (0.54) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL21795474 | 0.85 | TLR8 (0.52) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL21795300 | 0.85 | TLR8 (0.52) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL21795533 | 0.83 | TLR8 (0.53) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL23943030 | 0.82 | TLR8 (0.72) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL19000164 | 0.82 | TLR8 (0.57) | TLR8TLR9TLR7ARELANE | |
| SCHEMBL16661650 | 0.82 | TLR8 (0.72) | TLR8TLR9TLR7 | |
| SCHEMBL21795311 | 0.82 | TLR8 (0.54) | TLR8TLR9TLR7CTSBAR | |
| SCHEMBL16633689 | 0.82 | TLR8 (0.52) | TLR8TLR9TLR7AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844159-B1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2020043271-A1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, SSB, ARG2 | TLR8 1386/4885TLR9 583/4885TLR7 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.